The interactions of nonalcoholic fatty liver disease and cardiovascular diseases

Clinics in Liver Disease

Volumn 18, Issue 1, 2014, Pages 233-248

  Perazzo, Hugo ^a,b   Poynard, Thierry ^a,b,c   Dufour, Jean François ^d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Institute of Cardiometabolism and Nutrition (ICAN)   (France)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Atherosclerosis; Cardiovascular disease; Insulin resistance; Liver fibrosis; Nonalcoholic fatty liver disease

Indexed keywords

FATTY ACID;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE MARKER; DYSLIPIDEMIA; ECHOGRAPHY; FRAMINGHAM RISK SCORE; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; REVIEW;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; INSULIN RESISTANCE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER DISEASE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID STENOSIS; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIPOLYSIS; MALE; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS;

EID: 84888066099     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.09.014     Document Type: Review

References (90)

1. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140(1):124-131.
2. Adams L.A., Lindor K.D. Nonalcoholic fatty liver disease. Ann Epidemiol 2007, 17(11):863-869.
3. Harrison S.A., Neuschwander-Tetri B.A. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 2004, 8(4):861-879. ix.
4. Rafiq N., Bai C., Fang Y., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009, 7(2):234-238.
5. Edmison J., McCullough A.J. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 2007, 11(1):75-104. ix.
6. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123(1):134-140.
7. Wong V.W., Hui A.Y., Tsang S.W., et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006, 4(9):1154-1161.
8. Lizardi-Cervera J., Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009, 8(Suppl 1):S40-S43.
9. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50(8):1844-1850.
10. Budoff M.J., Achenbach S., Blumenthal R.S., et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006, 114(16):1761-1791.
11. Girshman J., Wolff S.D. Techniques for quantifying coronary artery calcification. Semin Ultrasound CT MR 2003, 24(1):33-38.
12. Wexler L., Brundage B., Crouse J., et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation 1996, 94(5):1175-1192.
13. Assy N., Djibre A., Farah R., et al. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010, 254(2):393-400.
14. Kim D., Choi S.Y., Park E.H., et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012, 56(2):605-613.
15. Chen C.H., Nien C.K., Yang C.C., et al. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci 2010, 55(6):1752-1760.
16. Akabame S., Hamaguchi M., Tomiyasu K., et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J 2008, 72(4):618-625.
17. Lorenz M.W., Markus H.S., Bots M.L., et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115(4):459-467.
18. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. NEngl J Med 1999, 340(1):14-22.
19. Caserta C.A., Pendino G.M., Amante A., et al. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am J Epidemiol 2010, 171(11):1195-1202.
20. Volzke H., Robinson D.M., Kleine V., et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005, 11(12):1848-1853.
21. Gastaldelli A., Kozakova M., Hojlund K., et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009, 49(5):1537-1544.
22. Kozakova M., Palombo C., Eng M.P., et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 2012, 55(5):1406-1415.
23. Sookoian S., Pirola C.J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. JHepatol 2008, 49(4):600-607.
24. Targher G., Bertolini L., Padovani R., et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006, 29(6):1325-1330.
25. Goland S., Shimoni S., Zornitzki T., et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. JClin Gastroenterol 2006, 40(10):949-955.
26. Fotbolcu H., Yakar T., Duman D., et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J 2010, 17(5):457-463.
27. Hallsworth K., Hollingsworth K.G., Thoma C., et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. JHepatol 2013, 58(4):757-762.
28. Fallo F., Dalla Pozza A., Sonino N., et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009, 19(9):646-653.
29. Yilmaz Y., Kurt R., Yonal O., et al. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis 2010, 211(1):182-186.
30. Targher G., Valbusa F., Bonapace S., et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 2013, 8(2):e57183.
31. Targher G., Mantovani A., Pichiri I., et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond) 2013, 125(6):301-309.
32. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129(1):113-121.
33. Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. JHepatol 2008, 49(4):608-612.
34. Dunn W., Xu R., Wingard D.L., et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008, 103(9):2263-2271.
35. Söderberg C., Stal P., Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51(2):595-602.
36. Adams L.A., Harmsen S., St Sauver J.L., et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010, 105(7):1567-1573.
37. Lazo M., Hernaez R., Bonekamp S., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011, 343:d6891.
38. Stepanova M., Younossi Z.M. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012, 10(6):646-650.
39. Bedogni G., Bellentani S., Miglioli L., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006, 6:33.
40. Calori G., Lattuada G., Ragogna F., et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011, 54(1):145-152.
41. Kim D., Kim W.R., Kim H.J., et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013, 57(4):1357-1365.
42. Angulo P., Hui J.M., Marchesini G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45(4):846-854.
43. Wai C.T., Greenson J.K., Fontana R.J., et al. Asimple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38(2):518-526.
44. Shah A.G., Lydecker A., Murray K., et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7(10):1104-1112.
45. Angulo P., Bugianesi E., Bjornsson E.S., et al. Simple non-invasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013, 145:782-789.
46. Dam-Larsen S., Becker U., Franzmann M.B., et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009, 44(10):1236-1243.
47. Targher G., Bertolini L., Rodella S., et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30(8):2119-2121.
48. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44(4):865-873.
49. Stepanova M., Rafiq N., Makhlouf H., et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013, 58:3017-3023.
50. Zhao X.Q., Krasuski R.A., Baer J., et al. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). Am J Cardiol 2009, 104(11):1457-1464.
51. Bhatia L.S., Curzen N.P., Calder P.C., et al. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J 2012, 33(10):1190-1200.
52. Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia 2008, 51(11):1947-1953.
53. Ruttmann E., Brant L.J., Concin H., et al. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005, 112(14):2130-2137.
54. Lee D.S., Evans J.C., Robins S.J., et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007, 27(1):127-133.
55. Lee D.H., Silventoinen K., Hu G., et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J 2006, 27(18):2170-2176.
56. Fraser A., Harris R., Sattar N., et al. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007, 27(12):2729-2735.
57. Schindhelm R.K., Dekker J.M., Nijpels G., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007, 191(2):391-396.
58. Yun K.E., Shin C.Y., Yoon Y.S., et al. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009, 205(2):533-537.
59. Hamaguchi M., Kojima T., Takeda N., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007, 13(10):1579-1584.
60. Arslan U., Turkoglu S., Balcioglu S., et al. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 2007, 18(6):433-436.
61. Kadayifci A., Tan V., Ursell P.C., et al. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. JHepatol 2008, 49(4):595-599.
62. Wong V.W., Wong G.L., Yip G.W., et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011, 60(12):1721-1727.
63. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114(4):842-845.
64. Kotronen A., Juurinen L., Tiikkainen M., et al. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 2008, 135(1):122-130.
65. Fabbrini E., Magkos F., Mohammed B.S., et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009, 106(36):15430-15435.
66. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990, 10(4):493-496.
67. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. JClin Invest 2006, 116(7):1793-1801.
68. Kotronen A., Westerbacka J., Bergholm R., et al. Liver fat in the metabolic syndrome. JClin Endocrinol Metab 2007, 92(9):3490-3497.
69. Despres J.P., Lemieux I., Bergeron J., et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008, 28(6):1039-1049.
70. van der Poorten D., Milner K.L., Hui J., et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008, 48(2):449-457.
71. Lavie C.J., Milani R.V., Verma A., et al. C-reactive protein and cardiovascular diseases-is it ready for primetime?. Am J Med Sci 2009, 338(6):486-492.
72. Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010, 103(2):71-83.
73. Videla L.A., Tapia G., Rodrigo R., et al. Liver NF-kappaB and AP-1 DNA binding in obese patients. Obesity (Silver Spring) 2009, 17(5):973-979.
74. McKimmie R.L., Daniel K.R., Carr J.J., et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 2008, 103(12):3029-3035.
75. Otsuka F., Sugiyama S., Kojima S., et al. Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men. Circ J 2007, 71(11):1703-1709.
76. Stefan N., Kantartzis K., Haring H.U. Causes and metabolic consequences of fatty liver. Endocr Rev 2008, 29(7):939-960.
77. Cai D., Yuan M., Frantz D.F., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005, 11(2):183-190.
78. Gaziano J.M., Hennekens C.H., O'Donnell C.J., et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997, 96(8):2520-2525.
79. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132(6):2169-2180.
80. Villanova N., Moscatiello S., Ramilli S., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005, 42(2):473-480.
81. Schindhelm R.K., Diamant M., Bakker S.J., et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest 2005, 35(6):369-374.
82. Kannel W.B., McGee D., Gordon T. Ageneral cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976, 38(1):46-51.
83. Framingham Heart Study Bibliography. Available at: Accessed June 6, 2013. http://www.framinghamheartstudy.org/biblio/index.html.
84. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
85. Cosin Aguilar J., Hernandiz Martinez A., Rodriguez Padial L., et al. Assessment of cardiovascular risk in population groups. Comparison of Score system and Framingham in hypertensive patients. Rev Clin Esp 2006, 206(4):182-187. [in Spanish].
86. Ford E.S., Giles W.H., Mokdad A.H. The distribution of 10-year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. JAm Coll Cardiol 2004, 43(10):1791-1796.
87. Jaquet A., Deloumeaux J., Dumoulin M., et al. Metabolic syndrome and Framingham risk score for prediction of cardiovascular events in Caribbean Indian patients with blood glucose abnormalities. Diabetes Metab 2008, 34(2):177-181.
88. Brindle P., Emberson J., Lampe F., et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003, 327(7426):1267.
89. Treeprasertsuk S., Leverage S., Adams L.A., et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012, 32(6):945-950.
90. Sung K.C., Ryan M.C., Wilson A.M. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis 2009, 203(2):581-586.